Gemtuzumab Ozogamicin in the Treatment of Acute Myeloid Leukemia

Cancer

Volumn 98, Issue 10, 2003, Pages 2095-2104

  Giles, Francis ^a   Estey, Elihli ^a   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; BUSULFAN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; INTERLEUKIN 11; LIPOSOME; OBLIMERSEN; RETINOIC ACID; TIOGUANINE; TOPOTECAN; TROXACITABINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; ASTHENIA; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORRELATION ANALYSIS; CYTOTOXICITY; DIARRHEA; DRUG APPROVAL; DRUG INFUSION; DYSPNEA; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HEPATIC TRANSAMINITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; HYPOXIA; IN VITRO STUDY; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; MUCOSA INFLAMMATION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SEPSIS; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ACUTE DISEASE; ADULT; AGE FACTORS; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMANS; IMMUNOTOXINS; LEUKEMIA, MYELOID; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0242695736     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11791     Document Type: Review

References (65)

1. Giles FJ, Keating A, Goldstone AH, Avivi I, Willman CL, Kantajian HM. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program). 2002;:73-110.
2. Tallman MS. Monoclonal antibody therapies in leukemias. Semin Hematol. 2002;39(4 Suppl 3):12-19.
3. Bernstein ID. CD33 as a target for selective ablation of acute myeloid leukemia. Clin Lymphoma. 2002;(2 Suppl 1):S9-S11.
4. Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia. 2000;14:474-475.
5. Giles FJ. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Rev Anti-cancer Ther. 2002;2:630-640.
6. Wellhausen SR, Pelper SC. CD33: biochemical and biological characterization and evaluation of clinical relevance. J Biol Regul Homeost Agents. 2002;16:139-143.
7. Jurcic JG. Antibody therapy of acute myelogenous leukemia. Cancer Biother Radiopharmacol. 2000; 15:319-326.
8. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res. 2000;6:372-380.
9. Jilani L, Estey E, Huh Y, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002; 118:560-566.
10. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97:3197-3204.
11. Dedon PC, Salzberg AA, Xu J. Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry. 1993;32:3617-3622.
12. LaMarr WA, Yu L, Nicolaou KC, Dedon PC. Supercoiling affects the accessibility of glutathione to DNA-bound molecules: positive supercoiling inhibits calicheamicin-induced DNA damage. Proc Natl Acad Sci USA. 1998;95:102-107.
13. Yu L, Goldberg IH, Dedon PC. Enediyne-mediated DNA damage in nuclei is modulated at the level of the nucleosome. J Biol Chem. 1994;269:4144-4151.
14. Kumar RA, Ikemoto N, Patel DJ. Solution structure of the calicheamicin gamma 1I-DNA complex. J Mol Biol. 1997; 265:187-201.
15. Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 1988;240: 1198-1201.
16. Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein expressing sublines. Leukemia. 2000;14:1436-1443.
17. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993; 53:3336-3342.
18. Hiatt A, Merlock R, Mauch S, Wrasidlo W. Regulation of apoptosis in leukemic cells by analogs of dynemicin A. Bioorg Med Chem. 1994;2:315-322.
19. Salzberg AA, Dedon PC. DNA bending is a determinant of calicheamicin target recognition. Biochemistry. 2000;39:7605-7612.
20. Lode HN, Reisfeld RA, Handgretinger R, Nicolaou KC, Gaedicke G, Wrasidlo W. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res. 1998;58:2925-2928.
21. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol. 2001;41:1206-1214.
22. Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin (Mylotarg®) in vitro. Role of Chk1 and Chk2 phosphorylation and caspase 3. Blood. 2003;6:6.
23. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a Phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-3684.
24. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
25. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
26. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16:1627-1636.
27. Leopold LH, Berger MS, Cheng SC, Cortes J, Giles F, Estey E. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in the treatment of patients with acute myeloid leukemia in first relapse. Clin Adv Hematol Oncol. 2003;1: 112-118.
28. Giles FJ. Novel agents for the therapy of acute leukemia. Curr Opin Oncol. 2002;14:3-9.
29. Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H, Estey E. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica. 2002;87:1114-1116.
30. Giles F, Garcia-Manero G, O'Brien S, Estey E, Kantarjian H. Fatal hepatic veno-occlusive disease in a Phase I study of Mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome. Acta Haematol. 2002;108:164-167.
31. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92:406-413.
32. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Pilot study of Mylotarg, liposomal daunorubicin, ara-C, and cyclosporine (MDAC) regimen in patients with refractory acute myelogenous leukemia. Leukemia Res. 2003;27:887-891.
33. Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol. 2003;51:87-90.
34. Cortes J, Tsimberidou AM, Alvarez R, et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol. 2002;50:497-500.
35. Tsimberidou A, Estey E, Cortes J, et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003;97:1481-1487.
36. Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia. Leukemia Res. 2003;27: 893-897.
37. Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98:988-994.
38. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98:3212-3220.
39. Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjian H. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs. 1999;17:81-87.
40. Tsimberidou A, Estey E, Cortes J, et al. Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. In press.
41. Giles FJ. Troxacitabine-based therapy of refractory leukemia. Expert Rev Anticancer Ther. 2002;2:261-266.
42. Giles FJ. New drugs in acute myeloid leukemia. Curr Oncol Rep. 2002;4:369-374.
43. Nicolaou KC, Stabila P, Esmaeli-Azad B, Wrasidlo W, Hiatt A. Cell-specific regulation of apoptosis by designed enediynes. Proc Natl Acad Sci USA 1993;90:3142-3146.
44. Nicolaou KC, Pitsinos EN, Theodorakis EA, Saimoto H, Wrasidlo W. Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis. Chem Biol. 1994;1:57-66.
45. Stadtmauer EA. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia. Clin Lymphoma. 2002;(2 Suppl 1):S24-S28.
46. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002;99:4343-4349.
47. Amadori S, Willemze R, Suciu S, et al. Sequential administration of gemtuzumab ozogamicin and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: interim results of the EORTC leukemia group AML - a Phase II trial [abstract]. Blood. 2001;98:587a.
48. Kell JW, (Burnett AK, Chopra R, Yin J. Effects of Mylotarg (gemtuzumab ozogomycin) in combination with standard induction chemotherapy in the treatment of acute myeloid leukaemia: a feasibility study [abstract]. Blood. 2001;98:123a.
49. Petti MC, Pinazzi MB, Diverio D, et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br J Haematol. 2001;115:63-65.
50. Tallman MS, Nabhan C. Management of acute promyelocytic leukemia. Curr Oncol Rep. 2002;4:381-389.
51. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin ("Mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002;99: 4222-4224.
52. Bearman SI. Veno-occlusive disease of the liver. Curr Opin Oncol. 2000;12:103-109.
53. Martin TG, Thall P, Giles FJ, et al. Allogeneic stem cell transplantation in individuals pretreated with gemtuzumab ozogamicin (Mylotarg™) during anti-leukemia therapy: incidence of VOD, organ toxicity, and GVHD. Bone Marrow Transplant. In press.
54. Tack DK, Letendre L, Kamath PS, Tefferi A. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant. 2001;28:895-897.
55. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:2310-2314.
56. Cohen AD, Luger SM, Sickles C, et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant. 2002;30:23-28.
57. Leopold LH, Berger MS, Feingold J. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. Clin Lymphoma. 2002;(2 Suppl 1):S29-S34.
58. Giles F, Cortes J, Halliburton T, et al. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother. 2003;37:1182-1185.
59. Sievers EL, Larson RA, Estey E, et al. Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676): relationship to hematopoietic stem cell transplantation [abstract]. Blood. 2000;96:206b.
60. Stadtmauer E, Larson R, Sievers E, et al. Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676) [abstract]. Blood. 2001;98:520a.
61. Langston A, Fienstein B, Hutcherson D, et al. Non-fatal veno-occlusive disease in non-transplant patients after treatment of relapsed AML with Mylotarg (gemtuzumab ozogamicin) [abstract]. Blood. 2001;98:201b.
62. Lech JA, Rossetti J, Lister J, et al. Hepatic venoocclusive disease as a complication of Mylotarg (gemtuzumab ozogamicin): the Western Pennsylvania Cancer Institute experience [abstract]. Blood. 2001;98:202b.
63. DeAngelo D, Russo D, Castaigne S, et al. Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia [abstract]. Blood. 2001;98:199b.
64. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000; 111:1122-1129.
65. McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma. 2002;(2 Suppl 1):S35-S39.